URC

URIC ACID

Created: 2002-03-15
Last modified:  2021-03-13

Find related ligands:

Chemical Details

Formal Charge0
Atom Count16
Chiral Atom Count0
Bond Count17
Aromatic Bond Count10
2D diagram of URC

Chemical Component Summary

NameURIC ACID
Synonyms7,9-DIHYDRO-1H-PURINE-2,6,8(3H)-TRIONE
Systematic Name (OpenEye OEToolkits)7,9-dihydro-3H-purine-2,6,8-trione
FormulaC5 H4 N4 O3
Molecular Weight168.11
TypeNON-POLYMER

Chemical Descriptors

TypeProgram Version Descriptor
SMILESACDLabs10.04O=C1C2=C(NC(=O)N1)NC(=O)N2
SMILESCACTVS3.341O=C1NC(=O)C2=C(N1)NC(=O)N2
SMILESOpenEye OEToolkits1.5.0C12=C(NC(=O)N1)NC(=O)NC2=O
Canonical SMILESCACTVS3.341 O=C1NC(=O)C2=C(N1)NC(=O)N2
Canonical SMILESOpenEye OEToolkits1.5.0 C12=C(NC(=O)N1)NC(=O)NC2=O
InChIInChI1.03 InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12)
InChIKeyInChI1.03 LEHOTFFKMJEONL-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank IDDB08844 
NameUric acid
Groups investigational
DescriptionUric acid is the last product of purine metabolism in humans. The formation of uric acid is through the enzyme xanthine oxidase, which oxidizes oxypurines. Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. At present (August 2013), there is no approved formulation or indication for uric acid. In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke.
Synonyms
  • 2,6,8-trioxypurine
  • 2,6,8-trihydroxypurine
  • Uricum acidum
  • Uric acid
  • Purine-2,6,8(1H,3H,9H)-trione
IndicationAt present (August 2013), there is no approved indication for uric acid. The potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke.
Categories
  • Alkaloids
  • Antioxidants
  • Biological Factors
  • Compounds used in a research, industrial, or household setting
  • Heterocyclic Compounds, Fused-Ring
CAS number69-93-2

Drug Targets

NameTarget SequencePharmacological ActionActions
Glycogen phosphorylase, liver form-unknown
Solute carrier family 22 member 6MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...unknown
Solute carrier family 22 member 8MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...unknown
Solute carrier family 2, facilitated glucose transporter member 9MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRK...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 5274273, 1175
ChEMBL CHEMBL792
ChEBI CHEBI:46823, CHEBI:62589, CHEBI:46811, CHEBI:46814, CHEBI:46817, CHEBI:17775
CCDC/CSD URICAC, URICAC06, URICAC05, URICAC04, URICAC03, URICAC02, GADGIF, URICAC01